Fusion Antibodies (LON:FAB) Issues Earnings Results

Fusion Antibodies (LON:FAB) announced its quarterly earnings data on Monday. The company reported GBX (1.20) EPS for the quarter, Digital Look Earnings reports. Fusion Antibodies had a negative net margin of 54.45% and a negative return on equity of 97.87%.

Fusion Antibodies Stock Up 2.3%

Shares of FAB traded up GBX 0.25 during trading hours on Friday, reaching GBX 11. The stock had a trading volume of 88,580 shares, compared to its average volume of 419,787. Fusion Antibodies has a 12 month low of GBX 9 and a 12 month high of GBX 21. The firm has a 50-day simple moving average of GBX 10.80 and a 200 day simple moving average of GBX 12.08. The company has a current ratio of 2.82, a quick ratio of 2.36 and a debt-to-equity ratio of 20.41. The company has a market capitalization of £13.77 million, a price-to-earnings ratio of -7.33 and a beta of 1.24.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.